Pfizer vs. Annora Pharma: Tofacitinib Patent Dismissal Explained
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Pfizer Inc. v. Annora Pharma Private Limited |
| Case Number | 1:25-cv-00424 (Del. Dist. Ct.) |
| Court | Delaware District Court |
| Duration | Apr 2025 – May 2025 39 days |
| Outcome | Plaintiff Dismissal – Without Prejudice |
| Patents at Issue | |
| Accused Products | Annora Pharma’s generic tofacitinib tablets (5 mg and 10 mg) |
Case Overview
The Parties
⚖️ Plaintiff
Global biopharmaceutical leader and the originator of Xeljanz® (tofacitinib), a Janus kinase (JAK) inhibitor approved for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
🛡️ Defendant
India-based generic pharmaceutical manufacturer with active ANDA (Abbreviated New Drug Application) filings targeting branded drug formulations in the U.S. market.
The Patent at Issue
The sole patent asserted was U.S. Reissue Patent RE41,783 (corrected application number US12/577790). Reissue patents are granted by the USPTO to correct errors in originally issued patents, often broadening or clarifying claims. RE41,783 covers tofacitinib’s core chemical and pharmaceutical compositions, making it a central pillar in Pfizer’s Xeljanz® exclusivity strategy.
- • US RE41,783 — Tofacitinib chemical and pharmaceutical compositions
Launching a generic drug?
Check if your tofacitinib formulation might infringe this or related patents.
The Verdict & Legal Analysis
Outcome
Pfizer filed a voluntary dismissal without prejudice pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i). No damages were awarded. No injunctive relief was granted or denied. Because the dismissal was entered without prejudice, Pfizer retains the right to refile substantially identical claims against Annora in the future.
Key Legal Issues
The dismissal highlights the strategic use of Rule 41(a)(1)(A)(i) in Hatch-Waxman litigation, allowing plaintiffs to trigger the 30-month FDA approval stay without committing to prolonged litigation. The case involved U.S. Reissue Patent RE41,783, covering tofacitinib’s core chemical composition, a critical asset in Pfizer’s Xeljanz® exclusivity strategy. The absence of substantive rulings means the validity and infringement of RE41,783 were not adjudicated.
Drafting pharmaceutical patents?
Learn from this case. Use AI to draft stronger claims for your drug formulations.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical compounds. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in the JAK inhibitor space
- See which companies are most active in pharmaceutical patents
- Understand claim construction patterns for chemical patents
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own drug formulation or product.
- Input your drug compound or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
JAK Inhibitor Compounds
Related Patents
In tofacitinib space
Hatch-Waxman Stay
30-month period triggered
✅ Key Takeaways
For Patent Attorneys & Litigators
Rule 41(a)(1)(A)(i) dismissals without prejudice preserve refiling rights and are a standard Hatch-Waxman enforcement tool.
Search related case law →Reissue patents carry unique invalidity risks (recapture rule) worth evaluating before trial.
Explore precedents →Chief Judge Connolly’s Delaware courtroom demands rigorous procedural compliance—choose counsel with deep local practice knowledge.
View Delaware court insights →For IP Professionals & R&D Teams
Track without-prejudice dismissals in competitor patent portfolios—they signal intent, not abandonment.
Start FTO analysis for my product →Generic product developers should conduct FTO analysis on reissue patents, which may have narrower or broader claims than their predecessors.
Try AI patent drafting →The 30-month Hatch-Waxman stay remains the pharmaceutical industry’s most consequential patent litigation tool for timeline planning.
Learn more about Hatch-Waxman →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.